Engineered immune cells take on tough lymphoma in new trial

NCT ID NCT07271121

Recruiting now Disease control Sponsor: King Hussein Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing a personalized cell therapy called MB-CART19.1 in 26 adults with CD19-positive non-Hodgkin lymphoma that has relapsed or not responded to prior treatments. The therapy uses a patient's own immune cells, which are modified in the lab to recognize and attack cancer cells. Participants receive a single dose and are monitored for one year to see how well it works and what side effects occur.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MB-CART19.1 (a type of CAR T-cell therapy made from the patient's own immune cells)
What this could lead to: If successful, this could offer a new treatment option for patients with hard-to-treat non-Hodgkin lymphoma that has come back or not responded to standard therapies.
What could go wrong: This is a small, single-center phase II trial, so results may not apply broadly. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma follicular lymphoma non-Hodgkin lymphoma primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN LYMPHOMA REFRACTORY/ RELAPSED

Contacts and locations

Locations

King Hussein Cancer Center
RECRUITING

Amman, 11941, Jordan

More trials for these conditions

Other studies related to the condition(s) this trial covers.